Leerink Partnrs Issues Negative Outlook for PTCT Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Investment analysts at Leerink Partnrs decreased their Q1 2026 earnings per share estimates for shares of PTC Therapeutics in a research report issued on Wednesday, October 15th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings per share of ($1.40) for the quarter, down from their previous forecast of ($1.32). The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. Leerink Partnrs also issued estimates for PTC Therapeutics’ Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($3.47) EPS and FY2027 earnings at ($3.82) EPS.

A number of other equities analysts also recently issued reports on PTCT. Wells Fargo & Company initiated coverage on PTC Therapeutics in a research note on Monday. They set an “overweight” rating and a $73.00 price target for the company. UBS Group lifted their price target on PTC Therapeutics from $71.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. Truist Financial lifted their price target on PTC Therapeutics from $80.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. Weiss Ratings reiterated a “hold (c-)” rating on shares of PTC Therapeutics in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $63.00 target price (up previously from $60.00) on shares of PTC Therapeutics in a research note on Friday, August 8th. Nine analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, PTC Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $69.00.

PTC Therapeutics Stock Performance

PTCT stock opened at $67.17 on Monday. The company has a market capitalization of $5.34 billion, a P/E ratio of 9.64 and a beta of 0.55. PTC Therapeutics has a 52-week low of $35.95 and a 52-week high of $69.48. The business has a 50-day simple moving average of $58.33 and a two-hundred day simple moving average of $51.40.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.24. The business had revenue of $178.88 million during the quarter, compared to the consensus estimate of $173.01 million. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The company’s quarterly revenue was down 4.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.29) EPS. PTC Therapeutics has set its FY 2025 guidance at EPS.

Insider Buying and Selling

In related news, Director Allan Steven Jacobson sold 12,000 shares of PTC Therapeutics stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $65.00, for a total value of $780,000.00. Following the sale, the director owned 17,451 shares of the company’s stock, valued at approximately $1,134,315. The trade was a 40.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David P. Southwell sold 12,000 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $58.34, for a total transaction of $700,080.00. Following the completion of the sale, the director directly owned 16,850 shares in the company, valued at $983,029. This trade represents a 41.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 249,735 shares of company stock worth $15,467,670 in the last three months. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On PTC Therapeutics

Hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP raised its holdings in shares of PTC Therapeutics by 545.5% in the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 551 shares during the period. PNC Financial Services Group Inc. raised its holdings in PTC Therapeutics by 84.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 320 shares during the period. GAMMA Investing LLC raised its holdings in PTC Therapeutics by 86.3% during the 1st quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 441 shares during the period. EverSource Wealth Advisors LLC raised its holdings in PTC Therapeutics by 247.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 814 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in PTC Therapeutics during the 1st quarter valued at $61,000.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.